Home LiteratureArticle Details

PMID: 17337768 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Review

Human tumor antigens, immunosurveillance, and cancer vaccines.

Immunologic research ·Vol. 36 ·No. 1-3 ·2006-00-00 ·Pages 73-82

Finn OJ

Abstract

Cancer is a serious health problem as well as a scientific challenge. A lot has been learned about the process of transformation of a normal cell into a tumor cell by studying genes and proteins that regulate this process either in cis or in trans. However, whether these molecular mechanisms succeed in fulfilling their potential to give a clinically evident disease depends in great measure on the host response to those molecular changes. The work of my laboratory aims to provide evidence in animal models as well as in cancer patients that immune system can control cancer growth and that this important function can be improved through vaccination with well-defined tumor antigens.

MeSH Terms

Animals Antigens, Neoplasm/immunology Cancer Vaccines/immunology Humans Immunologic Surveillance Neoplasms/immunology,prevention & control

Chemicals

Antigens, Neoplasm Cancer Vaccines

Authors & Affiliations

1 authors, click to expand affiliations / ORCID

Finn Olivera J

Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA. [email protected]

References (24)

24 references, click to expand

Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer.
Cancer Immunol Immunother. 2005 Mar;54(3):254-64 PMID: 15372205
T cell-dependent antibody responses against aberrantly expressed cyclin B1 protein in patients with cancer and premalignant disease.
Clin Cancer Res. 2005 Feb 15;11(4):1521-6 PMID: 15746055
Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells.
Proc Natl Acad Sci U S A. 1989 Sep;86(18):7159-63 PMID: 2674949
Suppressed T-cell receptor zeta chain expression and cytokine production in pancreatic cancer patients.
Clin Cancer Res. 2001 Mar;7(3 Suppl):933s-939s PMID: 11300494
The mechanism of unresponsiveness to circulating tumor antigen MUC1 is a block in intracellular sorting and processing by dendritic cells.
J Immunol. 2000 Oct 1;165(7):3730-41 PMID: 11034378
A decade in the life of tumor immunology.
Clin Cancer Res. 2001 Mar;7(3 Suppl):759s-760s PMID: 11300469
Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection.
J Immunol. 2001 Jun 1;166(11):6555-63 PMID: 11359807
Immune recognition of cyclin B1 as a tumor antigen is a result of its overexpression in human tumors that is caused by non-functional p53.
Mol Immunol. 2002 May;38(12-13):981-7 PMID: 12009577
Naturally processed class II epitope from the tumor antigen MUC1 primes human CD4+ T cells.
Cancer Res. 1998 Nov 15;58(22):5066-70 PMID: 9823312
Premalignant lesions as targets for cancer vaccines.
J Exp Med. 2003 Dec 1;198(11):1623-6 PMID: 14638849
Conditions associated with antibodies against the tumor-associated antigen MUC1 and their relationship to risk for ovarian cancer.
Cancer Epidemiol Biomarkers Prev. 2005 May;14(5):1125-31 PMID: 15894662
Tumor-rejection antigens recognized by T lymphocytes.
Curr Opin Immunol. 1993 Oct;5(5):701-8 PMID: 8240731
Complex carbohydrates are not removed during processing of glycoproteins by dendritic cells: processing of tumor antigen MUC1 glycopeptides for presentation to major histocompatibility complex class II-restricted T cells.
J Exp Med. 2002 Dec 2;196(11):1435-46 PMID: 12461079
Tumor antigens and tumor antigen discovery.
Cancer Treat Res. 2005;123:89-111 PMID: 16211867
Evaluation of anticyclin B1 serum antibody as a diagnostic and prognostic biomarker for lung cancer.
Ann N Y Acad Sci. 2005 Dec;1062:29-40 PMID: 16461786
Immune response as a biomarker for cancer detection and a lot more.
N Engl J Med. 2005 Sep 22;353(12):1288-90 PMID: 16177255
Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients.
Cancer Res. 2001 Jun 15;61(12):4756-60 PMID: 11406548
Human tumor antigen MUC1 is chemotactic for immature dendritic cells and elicits maturation but does not promote Th1 type immunity.
J Immunol. 2005 Aug 1;175(3):1628-35 PMID: 16034102
Identification of cyclin B1 as a shared human epithelial tumor-associated antigen recognized by T cells.
J Exp Med. 2001 Nov 5;194(9):1313-23 PMID: 11696596
Cancer vaccines: between the idea and the reality.
Nat Rev Immunol. 2003 Aug;3(8):630-41 PMID: 12974478
Presentation of MUC1 tumor antigen by class I MHC and CTL function correlate with the glycosylation state of the protein taken Up by dendritic cells.
Cell Immunol. 1999 Jun 15;194(2):143-9 PMID: 10383817
MUC1 immunobiology: from discovery to clinical applications.
Adv Immunol. 2004;82:249-93 PMID: 14975259
A new strategy for tumor antigen discovery based on in vitro priming of naive T cells with dendritic cells.
Clin Cancer Res. 2001 Mar;7(3 Suppl):773s-780s PMID: 11300472
A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma.
J Surg Res. 1996 Jun;63(1):298-304 PMID: 8667619

Article Info

Journal

Immunologic research

Abbr.

Immunol Res

ISSN

0257-277X

DOI

10.1385/IR:36:1:73

[email protected]

Published

2006-00-00

Pages

73-82

Language

English

Region

United States

NLM ID

8611087

Subset

External Links

PubMed source DOI: 10.1385/IR:36:1:73 View journal details

Analysis Services

Human tumor antigens, immunosurveillance, and cancer vaccines.

Contact

WeChat Official Account